BACKGROUND: Pathology of dorsolateral prefrontal cortex and dysregulation of dopaminergic neurons have been associated with the pathophysiology of schizophrenia, but how these phenomena relate to each other in patients has not been known. It has been hypothesized that prefrontal cortical pathology might induce both diminished steady-state and exaggerated responses of dopaminergic neurons to certain stimuli (e.g., stress). We examined the relationship between a measure of prefrontal neuronal pathology and striatal dopamine activity in patients with schizophrenia and in a nonhuman primate model of abnormal prefrontal cortical development. METHODS: In the patients, we studied in vivo markers of cortical neuronal pathology with NMR spectroscopic imaging and of steady-state striatal dopamine activity with radioreceptor imaging. In the monkeys, we used the same NMR technique and in vivo microdialysis. RESULTS: Measures of N-acetyl-aspartate concentrations (NAA) in dorsolateral prefrontal cortex strongly and selectively predicted D2 receptor availability in the striatum (n = 14, rho = -.64, p < .01), suggesting that the greater the apparent dorsolateral prefrontal cortex pathology, the less the steady-state dopamine activity in these patients. A similar relationship between NAA measures in dorsolateral prefrontal cortex and steady-state dopamine concentrations in the striatum was found in the monkeys (n = 5, rho = .70, p < .05). We then tested in the same monkeys the relationship of prefrontal NAA and striatal dopamine overflow following amphetamine infusion into dorsolateral prefrontal cortex. Under these conditions, the relationship was inverted, i.e., the greater the apparent dorsolateral prefrontal cortex pathology, the greater the dopamine release. CONCLUSIONS: These data demonstrate direct relationships between putative neuronal pathology in dorsolateral prefrontal cortex and striatal dopamine activity in human and nonhuman primates and implicate a mechanism for dopamine dysregulation in schizophrenia.
BACKGROUND: Pathology of dorsolateral prefrontal cortex and dysregulation of dopaminergic neurons have been associated with the pathophysiology of schizophrenia, but how these phenomena relate to each other in patients has not been known. It has been hypothesized that prefrontal cortical pathology might induce both diminished steady-state and exaggerated responses of dopaminergic neurons to certain stimuli (e.g., stress). We examined the relationship between a measure of prefrontal neuronal pathology and striatal dopamine activity in patients with schizophrenia and in a nonhuman primate model of abnormal prefrontal cortical development. METHODS: In the patients, we studied in vivo markers of cortical neuronal pathology with NMR spectroscopic imaging and of steady-state striatal dopamine activity with radioreceptor imaging. In the monkeys, we used the same NMR technique and in vivo microdialysis. RESULTS: Measures of N-acetyl-aspartate concentrations (NAA) in dorsolateral prefrontal cortex strongly and selectively predicted D2 receptor availability in the striatum (n = 14, rho = -.64, p < .01), suggesting that the greater the apparent dorsolateral prefrontal cortex pathology, the less the steady-state dopamine activity in these patients. A similar relationship between NAA measures in dorsolateral prefrontal cortex and steady-state dopamine concentrations in the striatum was found in the monkeys (n = 5, rho = .70, p < .05). We then tested in the same monkeys the relationship of prefrontal NAA and striatal dopamine overflow following amphetamine infusion into dorsolateral prefrontal cortex. Under these conditions, the relationship was inverted, i.e., the greater the apparent dorsolateral prefrontal cortex pathology, the greater the dopamine release. CONCLUSIONS: These data demonstrate direct relationships between putative neuronal pathology in dorsolateral prefrontal cortex and striatal dopamine activity in human and nonhuman primates and implicate a mechanism for dopamine dysregulation in schizophrenia.
Authors: Thomas W Weickert; Alejandro Terrazas; Llewellyn B Bigelow; James D Malley; Thomas Hyde; Michael F Egan; Daniel R Weinberger; Terry E Goldberg Journal: Learn Mem Date: 2002 Nov-Dec Impact factor: 2.460
Authors: Thomas W Weickert; Terry E Goldberg; Michael F Egan; Jose A Apud; Martijn Meeter; Catherine E Myers; Mark A Gluck; Daniel R Weinberger Journal: Biol Psychiatry Date: 2010-02-20 Impact factor: 13.382
Authors: Jong H Yoon; Andrew J Westphal; Michael J Minzenberg; Tara Niendam; J Daniel Ragland; Tyler Lesh; Marjorie Solomon; Cameron S Carter Journal: Schizophr Res Date: 2014-09-26 Impact factor: 4.939
Authors: Jong H Yoon; Michael J Minzenberg; Sherief Raouf; Mark D'Esposito; Cameron S Carter Journal: Biol Psychiatry Date: 2013-01-03 Impact factor: 13.382
Authors: Thomas W Weickert; Terry E Goldberg; Joseph H Callicott; Qiang Chen; Jose A Apud; Sumitra Das; Brad J Zoltick; Michael F Egan; Martijn Meeter; Catherine Myers; Mark A Gluck; Daniel R Weinberger; Venkata S Mattay Journal: J Neurosci Date: 2009-01-28 Impact factor: 6.167
Authors: Alessandro Bertolino; Paolo Taurisano; Nicola Marco Pisciotta; Giuseppe Blasi; Leonardo Fazio; Raffaella Romano; Barbara Gelao; Luciana Lo Bianco; Madia Lozupone; Annabella Di Giorgio; Grazia Caforio; Fabio Sambataro; Artor Niccoli-Asabella; Audrey Papp; Gianluca Ursini; Lorenzo Sinibaldi; Teresa Popolizio; Wolfgang Sadee; Giuseppe Rubini Journal: PLoS One Date: 2010-02-22 Impact factor: 3.240
Authors: Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams Journal: Psychopharmacology (Berl) Date: 2004-04-30 Impact factor: 4.530